• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

作者信息

Schalekamp Tom, Boink Gerard J J, Visser Loes E, Stricker Bruno H Ch, de Boer Anthonius, Klungel Olaf H

机构信息

Department of Pharmacoepidemiology and Pharmacotherapy, University Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

出版信息

Clin Pharmacol Ther. 2006 Jun;79(6):511-20. doi: 10.1016/j.clpt.2006.03.008.

DOI:10.1016/j.clpt.2006.03.008
PMID:16765138
Abstract
摘要

相似文献

1
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?醋硝香豆素治疗中的CYP2C9基因分型：它是国际标准化比值监测的一种具有成本效益的补充方法吗？
Clin Pharmacol Ther. 2006 Jun;79(6):511-20. doi: 10.1016/j.clpt.2006.03.008.
2
Acenocoumarol stabilization is delayed in CYP2C93 carriers.在CYP2C93携带者中，醋硝香豆素的稳定化延迟。
Clin Pharmacol Ther. 2004 May;75(5):394-402. doi: 10.1016/j.clpt.2003.12.017.
3
[Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].[细胞色素P450 2C9基因型对接受醋硝香豆素治疗患者出血并发症的意义]
Orv Hetil. 2005 Apr 17;146(16):739-43.
4
Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.细胞色素P450 2C9基因多态性与醋硝香豆素治疗
Kardiol Pol. 2006 Apr;64(4):397-402; discussion 403-4.
5
Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.CYP2C9 多态性对香豆素类药物华法林相互作用易感性的影响。
Pharmacogenomics. 2013 May;14(7):745-53. doi: 10.2217/pgs.13.55.
6
Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.
Blood Coagul Fibrinolysis. 2003 Dec;14(8):761-4. doi: 10.1097/00001721-200312000-00012.
7
Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.质子泵抑制剂与华法林维持治疗期间过度抗凝的风险。
Br J Haematol. 2011 May;153(3):379-85. doi: 10.1111/j.1365-2141.2011.08633.x. Epub 2011 Mar 21.
8
Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Pharmacogenetics. 2001 Nov;11(8):735-7. doi: 10.1097/00008571-200111000-00013.
9
Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.在存在CYP2C9突变的情况下醋硝香豆素和苯妥英的毒性
J Assoc Physicians India. 2008 Apr;56:250-2.
10
CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Clin Pharmacol Ther. 2004 May;75(5):376-80. doi: 10.1016/j.clpt.2004.01.007.

引用本文的文献

1
Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation.药物遗传学检测预防药物不良反应：系统评价经济评估以及对临床实践和实施的质量评估。
BMC Health Serv Res. 2021 Oct 2;21(1):1042. doi: 10.1186/s12913-021-07025-8.
2
Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.系统评价遗传药理学指导心血管疾病治疗的成本效益的证据。
Genet Med. 2020 Mar;22(3):475-486. doi: 10.1038/s41436-019-0667-y. Epub 2019 Oct 8.
3
Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.
支持在随机对照试验中纳入药物遗传生物标志物的证据。
J Pers Med. 2019 Sep 1;9(3):42. doi: 10.3390/jpm9030042.
4
A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.药物基因检测预防药物不良反应的经济学评价系统综述
Pharmacoeconomics. 2016 Aug;34(8):771-93. doi: 10.1007/s40273-016-0397-9.
5
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.药物遗传学和药物基因组学筛查试验的经济学评估：系统评价。文献的第二次更新
PLoS One. 2016 Jan 11;11(1):e0146262. doi: 10.1371/journal.pone.0146262. eCollection 2016.
6
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.两种不同欧洲医疗环境下新型口服抗凝剂用于心房颤动患者预防卒中的成本效益
Am J Cardiovasc Drugs. 2014 Dec;14(6):451-62. doi: 10.1007/s40256-014-0092-1.
7
Cost effectiveness of pharmacogenomics: a critical and systematic review.药物基因组学的成本效益：批判性和系统性综述。
Pharmacoeconomics. 2010;28(11):1001-13. doi: 10.2165/11537410-000000000-00000.
8
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.药物遗传学和基因组筛查项目的药物经济学评估：关于内容及对指南遵循情况的系统评价
Pharmacoeconomics. 2008;26(7):569-87. doi: 10.2165/00019053-200826070-00005.
9
Warfarin pharmacogenetics: economic considerations.华法林药物遗传学：经济考量
Pharmacoeconomics. 2007;25(11):899-902. doi: 10.2165/00019053-200725110-00001.
10
CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.巴西患者中CYP2C9基因分型与华法林治疗的抗凝控制质量
Eur J Clin Pharmacol. 2008 Jan;64(1):9-15. doi: 10.1007/s00228-007-0385-2. Epub 2007 Oct 23.